Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leslie Citrome

Psychiatry Pomona, NY Medical Doctor

NPI 1780796045 CMS profile 171564

11 Medical Park Dr, Suite 106, Pomona, NY 10970

Open in the dashboard

General payments

$5,699,751

5,190 records reported · program years 2019–2025

Research payments

$36,033

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leslie Citrome of Pomona, NY is reported in the CMS Open Payments database as having received $5,699,751 across 5,190 general payments and $36,033 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,000,908 914
2025 Research $3,150 4
2024 General $1,045,523 975
2024 Research $11,970 1
2023 General $1,032,402 956
2023 Research $6,563 2
2022 General $860,237 736
2021 General $548,571 393
2021 Research $1,050 1
2020 General $523,811 373
2020 Research $8,750 4
2019 General $688,298 843
2019 Research $4,550 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leslie Citrome
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Leslie Citrome were reported at $1,000,908. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Leslie Citrome Psychiatry median Middle half National median
2019 $688,298 $184 $59–$605 $163
2020 $523,811 $119 $36–$372 $114
2021 $548,571 $143 $43–$576 $132
2022 $860,237 $153 $50–$590 $149
2023 $1,032,402 $170 $56–$651 $160
2024 $1,045,523 $179 $57–$673 $164
2025 $1,000,908 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $967,666 789 payments
  2. Alkermes, Inc. $694,692 675 payments
  3. Otsuka America Pharmaceutical, Inc. $671,530 929 payments
  4. Neurocrine Biosciences, Inc. $614,721 614 payments
  5. AbbVie, Inc. $446,907 337 payments
  6. ITI, Inc. $379,612 275 payments
  7. Axsome Therapeutics, Inc. $268,876 270 payments
  8. H. Lundbeck A S $247,066 90 payments
  9. E.R. Squibb & Sons, L.L.C. $224,620 168 payments
  10. Eisai Inc. $222,022 135 payments
  11. Other $962,040 908 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,233,234 1,111 payments
  2. Consulting Fee $1,358,098 338 payments
  3. Travel and Lodging $710,223 2,296 payments
  4. Honoraria $306,830 72 payments
  5. Food and Beverage $87,850 1,368 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $3,488 1 payment
  7. Education $28 4 payments
Products named General payments · program years 2019–2025
  1. REXULTI $513,988 727 payments
  2. LYBALVI Cns $384,189 382 payments
  3. INGREZZA $382,691 353 payments
  4. AUSTEDO $381,866 288 payments
  5. LYBALVI Cns $371,662 359 payments
  6. LYBALVI Cns $371,539 358 payments
  7. LYBALVI Cns $371,539 358 payments
  8. VRAYLAR $360,590 298 payments
  9. UZEDY $302,406 278 payments
  10. ARISTADA $297,741 295 payments
  11. Other $4,066,964 3,718 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $15,120 5 payments
  2. Teva Pharmaceuticals USA, Inc. $14,350 7 payments
  3. Vanda Pharmaceuticals Inc. $6,563 2 payments

Records

5,204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record